Hayek Kallen Investment Management lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.1% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,078 shares of the medical research company’s stock after selling 409 shares during the quarter. Thermo Fisher Scientific comprises 3.6% of Hayek Kallen Investment Management’s holdings, making the stock its 7th largest holding. Hayek Kallen Investment Management’s holdings in Thermo Fisher Scientific were worth $5,603,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the stock. Truvestments Capital LLC purchased a new position in shares of Thermo Fisher Scientific in the first quarter worth about $29,000. Liberty Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $35,000. CX Institutional purchased a new position in shares of Thermo Fisher Scientific in the first quarter worth about $36,000. Somerset Trust Co raised its stake in shares of Thermo Fisher Scientific by 162.7% in the first quarter. Somerset Trust Co now owns 197 shares of the medical research company’s stock worth $54,000 after purchasing an additional 122 shares during the last quarter. Finally, Farmers & Merchants Trust Co of Chambersburg PA raised its stake in shares of Thermo Fisher Scientific by 168.0% in the first quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 201 shares of the medical research company’s stock worth $55,000 after purchasing an additional 126 shares during the last quarter. 88.02% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific stock traded down $3.38 during midday trading on Friday, hitting $287.21. 1,274,001 shares of the company were exchanged, compared to its average volume of 1,472,728. The company has a market cap of $114.88 billion, a price-to-earnings ratio of 24.51, a PEG ratio of 1.88 and a beta of 1.10. Thermo Fisher Scientific Inc. has a fifty-two week low of $208.34 and a fifty-two week high of $305.45. The stock’s fifty day simple moving average is $291.39. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.49 and a quick ratio of 1.16.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $3.04 EPS for the quarter, topping the consensus estimate of $3.01 by $0.03. The firm had revenue of $6.32 billion for the quarter, compared to analyst estimates of $6.31 billion. Thermo Fisher Scientific had a return on equity of 17.11% and a net margin of 14.24%. Thermo Fisher Scientific’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same period last year, the company earned $2.75 earnings per share. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 12.23 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Tuesday, September 17th will be issued a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a yield of 0.26%. The ex-dividend date is Monday, September 16th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 6.83%.

In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $268.29, for a total value of $670,725.00. Following the sale, the chief financial officer now directly owns 40,029 shares of the company’s stock, valued at $10,739,380.41. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director C Martin Harris sold 275 shares of the firm’s stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $270.73, for a total value of $74,450.75. Following the completion of the sale, the director now directly owns 6,433 shares in the company, valued at $1,741,606.09. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 53,488 shares of company stock worth $14,600,474. 0.45% of the stock is owned by corporate insiders.

Several research analysts have recently issued reports on the company. UBS Group cut AGL Energy to a “sell” rating in a research note on Thursday, May 23rd. Bank of America cut Propetro from a “buy” rating to a “neutral” rating in a research note on Tuesday, April 16th. BTIG Research raised their price objective on Thermo Fisher Scientific to $320.00 and gave the stock a “buy” rating in a research note on Thursday, May 23rd. Wolfe Research initiated coverage on Waters in a report on Thursday, May 30th. They set an “underperform” rating on the stock. Finally, Barclays set a $330.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Monday, July 15th. Two investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $302.55.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

See Also: What is a stock split?

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.